凯赛生物
(688065)
| 流通市值：219.76亿 | | | 总市值：271.71亿 |
| 流通股本：5.83亿 | | | 总股本：7.21亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,837,905,343.41 | 1,900,180,844.78 | 874,529,796.39 | 3,295,051,930.28 |
| 营业收入 | 2,837,905,343.41 | 1,900,180,844.78 | 874,529,796.39 | 3,295,051,930.28 |
| 二、营业总成本 | 2,280,880,449.35 | 1,508,819,010.42 | 715,775,081.82 | 2,575,128,035.09 |
| 营业成本 | 1,853,480,856.87 | 1,221,182,750.71 | 559,349,019.11 | 2,167,646,190.24 |
| 税金及附加 | 26,517,342.82 | 18,849,766.16 | 8,747,718.02 | 33,459,110.05 |
| 销售费用 | 44,924,526.76 | 30,609,457.06 | 14,858,727.05 | 60,062,652.36 |
| 管理费用 | 151,218,820.04 | 99,051,746.45 | 49,445,931.49 | 174,935,755.6 |
| 研发费用 | 205,651,046.73 | 126,663,427.67 | 56,867,479.51 | 237,891,987.96 |
| 财务费用 | -912,143.87 | 12,461,862.37 | 26,506,206.64 | -98,867,661.12 |
| 其中:利息费用 | 3,819,617.43 | 2,803,510.76 | 1,541,390.4 | 8,790,803.27 |
| 其中:利息收入 | 161,319,755.15 | 122,158,556.93 | 35,119,603.53 | 184,200,749.03 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 2,132,753.46 | - | - | - |
| 加:投资收益 | -14,766,031.94 | -8,590,217.15 | -3,760,331.64 | 1,401,691.68 |
| 资产处置收益 | -36,266.15 | -18,664.22 | -5,422.84 | 6,708,160.46 |
| 资产减值损失(新) | -15,715,358.81 | -14,865,823.26 | 9,301,737.32 | -135,700,535.02 |
| 信用减值损失(新) | -5,985,903.51 | -6,033,789.88 | -2,178,134.41 | -11,728,738.54 |
| 其他收益 | 56,340,617.28 | 39,015,796.74 | 30,330,082.42 | 53,148,654.76 |
| 四、营业利润 | 578,994,704.39 | 400,869,136.59 | 192,442,645.42 | 633,753,128.53 |
| 加:营业外收入 | 28,143,746.51 | 27,907,058.46 | 125,935.07 | 726,675.26 |
| 减:营业外支出 | 2,390,734.96 | 1,781,089.76 | 510,050.9 | 4,314,974.85 |
| 五、利润总额 | 604,747,715.94 | 426,995,105.29 | 192,058,529.59 | 630,164,828.94 |
| 减:所得税费用 | 81,058,558.89 | 57,330,084.64 | 27,684,804.25 | 100,662,520.83 |
| 六、净利润 | 523,689,157.05 | 369,665,020.65 | 164,373,725.34 | 529,502,308.11 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 523,689,157.05 | 369,665,020.65 | 164,373,725.34 | 529,502,308.11 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 526,955,811.7 | 372,730,644.26 | 165,716,872.97 | 560,720,036.93 |
| 少数股东损益 | -3,266,654.65 | -3,065,623.61 | -1,343,147.63 | -31,217,728.82 |
| 扣除非经常损益后的净利润 | 476,263,236.82 | 328,704,238.08 | 147,633,535.85 | 520,694,503.24 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.73 | 0.52 | 0.23 | 0.82 |
| (二)稀释每股收益 | 0.73 | 0.52 | 0.23 | 0.82 |
| 八、其他综合收益 | -1,293,488.83 | -149,243.52 | 159,103.82 | 4,771,479.52 |
| 归属于母公司股东的其他综合收益 | -1,293,488.83 | -149,243.52 | 159,103.82 | 4,771,479.52 |
| 九、综合收益总额 | 522,395,668.22 | 369,515,777.13 | 164,532,829.16 | 534,273,787.63 |
| 归属于母公司股东的综合收益总额 | 525,662,322.87 | 372,581,400.74 | 165,875,976.79 | 565,491,516.45 |
| 归属于少数股东的综合收益总额 | -3,266,654.65 | -3,065,623.61 | -1,343,147.63 | -31,217,728.82 |
| 公告日期 | 2026-10-31 | 2026-08-20 | 2026-04-30 | 2026-04-24 |
| 审计意见(境内) | | | | 标准无保留意见 |